Cullinan Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026New directors help oversee company decisions and ensure shareholder interests are protected.
Early clinical success suggests the drug may work for patients who failed other treatments, potentially opening new markets.
Public presentation of clinical results helps investors understand drug potential and company progress toward commercialization.
Upcoming clinical data announcements give investors visibility into pipeline progress and potential future value drivers.
Quarterly earnings show cash position, burn rate, and operational spending critical to assessing runway and business health.
Quarterly earnings show cash position, burn rate, and operational spending critical to assessing runway and business health.
Annual results reveal total revenue, expenses, cash balance, and clinical progress needed to evaluate company viability.
Stocky reads Cullinan Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Cullinan Therapeutics, Inc.'s most recent tracked filing was a 8-K on 16 Jun 2026: Stockholders elect Nadim Ahmed and Stephen Webster to board.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.